June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Macular flow in von Hippel-Lindau disease
Author Affiliations & Notes
  • Elisabetta Pilotto
    Department of Ophthalmology, University of Padova, Padova, Italy
  • Elisabetta Beatrice Nacci
    Department of Ophthalmology, University of Padova, Padova, Italy
  • Alfonso Massimiliano Ferrara
    Familial Tumor Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Padova, Italy
  • Gilda De Mojà
    Department of Ophthalmology, University of Padova, Padova, Italy
  • Raffaele Parrozzani
    Department of Ophthalmology, University of Padova, Padova, Italy
  • Stefania Zovato
    Familial Tumor Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Padova, Italy
  • Edoardo Midena
    Department of Ophthalmology, University of Padova, Padova, Italy
    Fondazione Bietti, IRCCS, Rome, Italy, Italy
  • Footnotes
    Commercial Relationships   Elisabetta Pilotto, None; Elisabetta Beatrice Nacci, None; Alfonso Massimiliano Ferrara, None; Gilda De Mojà, None; Raffaele Parrozzani, None; Stefania Zovato, None; Edoardo Midena, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 2563. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elisabetta Pilotto, Elisabetta Beatrice Nacci, Alfonso Massimiliano Ferrara, Gilda De Mojà, Raffaele Parrozzani, Stefania Zovato, Edoardo Midena; Macular flow in von Hippel-Lindau disease. Invest. Ophthalmol. Vis. Sci. 2020;61(7):2563.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate, using optical coherence tomography angiography (OCT-A), macular retinal capillary flow in patients with Von Hippel–Lindau (VHL) disease without or with peripheral retinal hemangioblastomas.

Methods : Patients with VHL disease were consecutively enrolled in this cross-sectional study. Eyes with retinal hemangioblastomas at the posterior pole, macular pucker on any other macular disease were excluded. Age-matched healthy subjects were enrolled as controls. All included eyes were evaluated with OCT-A (Spectralis HRA+OCTA, Heidelberg Engineering). Using OCT en face angiograms, automatically segmented, macular perfusion was analyzed in the superficial (SCP), intermediate (ICP) and deep retinal capillary plexuses (DCP). Quantitative analysis of the vascular plexuses was performed using an open-source available ImageJ software (National Institutes of Health, Bethesda, Maryland, USA). The following OCT-A vascular parameters were measured: vessel area density (VAD); vessel length fraction (VLF); vessel diameter index (VDI) and fractal dimension (FD).

Results : Forty-four VHL patients (81 eyes) and 20 healthy controls (40 eyes) were enrolled. In VHL eyes, macular perfusion was significantly reduced compared to controls (p< 0.005 for all OCT-A parameters) in all capillary plexuses. No differences were detected between eyes without or with retinal hemangioblastomas.

Conclusions : Macular flow is reduced in patients with VHL disease, even in absence of retinal hemangioblastomas. These results could be explained considering the pathophysiology of VHL: the disruption of the hypoxia-induced factors (HIF)/vascular endothelium growth factor (VEGF) signaling, that leads to abnormal vascular remodeling, and the aberrant Notch signaling, which plays an important role in both vasculogenesis and angiogenesis. These results seem to validate the hypothesis of the VHL disease- associated hemangioblastoma as a developmental, rather than a neoplastic, phenomenon.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×